Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GCGR | P47871 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411254 | 1.00 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EMEN1KMT2AGCGR | |
| SCHEMBL22118349 | 0.87 | CYP1A1 (0.45) | SMN1; SMN2MEN1KMT2AGCGRMAPK14 | |
| SCHEMBL24098965 | 0.85 | NPY5R (0.42) | SMN1; SMN2KDM4EMEN1KMT2AGCGR | |
| SCHEMBL30411455 | 0.83 | CYP1A1 (0.44) | ADORA2ACYP1A1GSK3AGSK3BNPY5R | |
| SCHEMBL24107972 | 0.83 | CYP1A1 (0.44) | ADORA2ACYP1A1GSK3AGSK3BNPY5R | |
| SCHEMBL24107996 | 0.83 | KDM4E (0.49) | SMN1; SMN2KDM4EMEN1KMT2AGCGR | |
| SCHEMBL30340295 | 0.83 | KDM4E (0.49) | SMN1; SMN2KDM4EMEN1KMT2AGCGR | |
| SCHEMBL26045173 | 0.82 | NPC1 (0.48) | SMN1; SMN2KDM4EMEN1KMT2AGCGR | |
| SCHEMBL24108490 | 0.82 | KDM4E (0.42) | SMN1; SMN2KDM4EMEN1KMT2AMAPK14 | |
| SCHEMBL30340709 | 0.82 | KDM4E (0.42) | SMN1; SMN2KDM4EMEN1KMT2AMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| WO-2021252859-A1 | INHIBITORS OF APOL1 AND USE OF THE SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | SMN1; SMN2 2720/4885KDM4E 4564/4885MEN1 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.